CN105582017A - Composition for treating gastric ulcer combined gastrointestinal bleeding and preparation method of composition - Google Patents
Composition for treating gastric ulcer combined gastrointestinal bleeding and preparation method of composition Download PDFInfo
- Publication number
- CN105582017A CN105582017A CN201610097583.3A CN201610097583A CN105582017A CN 105582017 A CN105582017 A CN 105582017A CN 201610097583 A CN201610097583 A CN 201610097583A CN 105582017 A CN105582017 A CN 105582017A
- Authority
- CN
- China
- Prior art keywords
- ginseng
- ginsenoside
- composition
- pseudo
- gastric ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 33
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims description 29
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 title abstract 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 title abstract 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims abstract description 27
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims abstract description 27
- RAQNTCRNSXYLAH-RFCGZQMISA-N (20S)-ginsenoside Rh1 Chemical compound O([C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RAQNTCRNSXYLAH-RFCGZQMISA-N 0.000 claims abstract description 25
- RAQNTCRNSXYLAH-UHFFFAOYSA-N Ginsenoside Rh1 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(C3)C)(C)C1C(O)CC2C1(C)CCC(O)C(C)(C)C1C3OC1OC(CO)C(O)C(O)C1O RAQNTCRNSXYLAH-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 113
- 244000131316 Panax pseudoginseng Species 0.000 claims description 56
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 239000003480 eluent Substances 0.000 claims description 35
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 27
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 27
- 235000008434 ginseng Nutrition 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 17
- 238000010992 reflux Methods 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 239000008367 deionised water Substances 0.000 claims description 11
- 229910021641 deionized water Inorganic materials 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 8
- 235000012054 meals Nutrition 0.000 claims description 8
- 238000003809 water extraction Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 2
- 239000004223 monosodium glutamate Substances 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229960003885 sodium benzoate Drugs 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 1
- 239000000605 aspartame Substances 0.000 claims 1
- 229960003438 aspartame Drugs 0.000 claims 1
- 235000010357 aspartame Nutrition 0.000 claims 1
- 235000008504 concentrate Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000023555 blood coagulation Effects 0.000 abstract description 4
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 206010061164 Gastric mucosal lesion Diseases 0.000 abstract 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 description 21
- 208000025865 Ulcer Diseases 0.000 description 15
- 231100000397 ulcer Toxicity 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical group N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241001313855 Bletilla Species 0.000 description 2
- 241001233914 Chelidonium majus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940068560 greater celandine Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009854 mucosal lesion Effects 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- -1 0.5-2mg Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a composition for treating a gastric ulcer combined gastrointestinal bleeding. The composition comprises the following active components in parts by weight: 8-25 parts of ginsenoside Re, 10-30 parts of ginsenoside Rg3 and 5-20 parts of ginsenoside Rh1. The composition has the effects of obviously improving the gastric mucosal lesion and gastric mucosal lesion, promoting the blood coagulation and stopping bleeding, and is capable of effectively treating and/or preventing gastrointestinal diseases of the gastric ulcer combined gastrointestinal bleeding and the like.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of composition and preparation thereof for the treatment of gastric ulcer merging hemorrhage of gastrointestinal tractMethod.
Background technology
In recent years, along with improving constantly of people's living standard, there is very large change in people's life style, followsAnd what come is that the incidence of disease and the illness rate of enterogastric diseases is all obvious ascendant trend. Gastric ulcer is in gastrointestinal system diseaseCommon disease, frequently-occurring disease, this disease is easy to merge and occurs gastrorrhagia, and main manifestations is stomachache, gasteremphraxis, suffers from diarrhoea, has blood in stool, vomits clinicallyThe symptoms such as blood, in traditional Chinese medicine, belong to the category such as " epigastric pain ", " ruffian is full ".
Aspect etiology and pathogenesis, the generation of the enterogastric diseases such as gastric ulcer, gastrorrhagia, think more main and weakness of the spleen and the stomach,The factors such as disorder of emotion, injury due to diet, being invaded by exogenous pathogen,invasion of exogenous pathogen are relevant, and wherein weakness of the spleen and the stomach is pathologic basis, the many simulataneous insufficiency and excessive of characteristic of disease. InMedical science is thought: overstrain, and injury due to diet, prolonged illness, plain body does not wait and all can undermine spleen sun, causes weakness of the spleen and the stomach.
Clinically, the enterogastric diseases such as gastric ulcer, gastrorrhagia that deficiency-cold in spleen and stomach is caused, doctor trained in Western medicine mainly adopts and presses down acid, onlyBitterly, the methods for the treatment of such as antidiarrheal, traditional Chinese medicine adopts warming stomach for dispelling cold, blood stasis removing analgesic, warming spleen and stopping diarrha method. Traditional Chinese medicine treatment at presentThis sick curative effect is proved, further adopts Chinese medicine extract to study, and more can give full play to the advantage of traditional Chinese medicine.
In recent years, the research of the each side such as extraction process, chemical composition and the pharmacological action of people to pseudo-ginseng is more and more.Modern study shows, the main chemical compositions of pseudo-ginseng comprises saponins, flavonoids, volatile oil, carbohydrate etc., and tcm clinical practice confirms threeSeven have loose stasis of blood hemostasis, the effect of detumescence ding-tong; Modern medicine study confirms that pseudo-ginseng has significantly and controls human body cardiovascular and cerebrovascular diseaseTreatment effect, have simultaneously hypoglycemic, anti-hypertension, antitumor, anticancer, protect the liver effects such as protecting kidney. Clinical pharmacology research shows, pseudo-ginsengWater extract-alcohol precipitation has certain protective effect to mucosal lesion; Saponin has good hemostasia effect, can be by carryingHigh platelet counts and ability of aggregation, shorten the hemorrhage and clotting time, reaches anastalsis.
CN1589808A " a kind of pharmaceutical composition and preparation technology and purposes for the treatment of peptic ulcer or enteritis ", itsActive principle is: herba fibraureae recisae alkaloid, arasaponin, bletilla polysaccharide, greater celandine alkaloid, its preparation method is: by every (orEvery of person, every ball) in contain in essence the herba fibraureae recisae alkaloid of 36-90mg, the arasaponin of 30-75mg, the bletilla of 30-75mgFour kinds of effective one-tenth of greater celandine alkaloid of polysaccharide, 0.5-2mg, mix rear pulverizing by these four kinds of effective ingredients preparations, cross 80～180 mesh sieves, reinstall capsule (soft, hard shell capsules for common drug) and make capsule (soft capsule, hard capsule), or further addAdd medicinal solvent or excipient, anticorrisive agent, adopt common pharmaceutical technology, make pill or granule, tablet. This patent is disclosedPurposes is the ulcer that treatment peptic ulcer class illness and helicobacter pylori cause, duodenal ulcer, and acute and chronic gastritis,Bacillary dysentery, enteritis, diarrhoea illness or be further used for preparation treatment peptic ulcer class medicine, but and not mentioned this medicine haveTreatment gastrorrhagia or treatment gastric ulcer merge the effect of gastrorrhagia.
Summary of the invention
The object of this invention is to provide a kind of composition that gastric ulcer merges hemorrhage of gastrointestinal tract for the treatment of;
The object of this invention is to provide a kind of preparation method that gastric ulcer merges the composition of hemorrhage of gastrointestinal tract that treats.
The object of the invention is to realize by following technical scheme:
Raw material sources of the present invention:
Pseudo-ginseng is dry root and the rhizome of Araliaceae Parmxnotoginseng (Burk.) F.H.Chen. Autumn, the flowers are in blossomBefore excavate, clean, separately main root, a root and rhizome, dry. Supporting root is practised and is claimed " rib ", and rhizome is practised title " clip ". [nature and flavor with returnThrough] sweet, micro-hardship, temperature. Return liver, stomach warp. [function with cure mainly] loose stasis of blood hemostasis, detumescence ding-tong. For spitting of blood, spit blood, Carp blood, justBlood, uterine bleeding, traumatism and bleeding, chest ventral spine pain, treating swelling and pain by traumatic injury.
The extracting method of inventor to ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 in pseudo-ginseng of the present invention andIts curative effect has been carried out a large amount of systematic experimental studies, has finally obtained extractive technique scheme of the present invention, and the present invention adopts solelySpecial extract, purifying process resulting composition, its special character is, described composition is made up of the following composition of proportioning: ginsengSaponin(e Re:8～25 part, ginseng sapoglycoside Rg 3: 10～30 parts, ginsenoside Rh 1: 5～20 parts.
Preferably, arasaponin of the present invention, it is to be made up of the following composition of proportioning: ginsenoside Re: 15～25 parts, ginseng sapoglycoside Rg 3: 15～30 parts, ginsenoside Rh 1: 15～20 parts.
Preferably, arasaponin of the present invention, it is to be made up of the following composition of proportioning: ginsenoside Re: 25Part, ginseng sapoglycoside Rg 3: 25 parts, ginsenoside Rh 1: 15 parts.
The invention also discloses and there is the method that treatment gastric ulcer merges the composition of hemorrhage of gastrointestinal tract effect a kind of preparation, concreteStep is as follows:
(1) Radix Notoginseng powder is broken into 40 order meal, adding 20 times of percents by volume of medicinal material weight is that 70-80% alcohol reflux extracts 2～3Inferior, each 1～3h, filters, and merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 10-15 times of water refluxing extraction 2 of medicinal material weight againInferior, each 1～2h, filters, and merging filtrate, obtains pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, concentrated, dry, obtain threeSeven dry extracts; Pseudo-ginseng dry extract, adds a small amount of ethanol to dissolve, by D101 macroporous adsorbent resin column chromatography, first with 1-4BV go fromSub-water elution, discards eluent; Be 70-80% ethanol elution by 2-6BV percent by volume again, elution speed is 1～3BV/H, merges ethanol eluate, reclaims solvent, dry, obtains arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 resin column, with 1～4BV deionized water wash-out, discards eluent;With 1～3BV15% ethanolic solution wash-out, discard eluent; Use successively 2～5BV30%, 2～5BV50%, 2～4BV75%Ethanol elution, elution speed is 2～5BV/h, collects respectively each section of eluent, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsengThe eluent of saponin(e Rh1, reduced pressure concentration, dry;
(3), by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by weight portion described in claim 1, to obtain final product.
Preferably, preparation method is:
(1) Radix Notoginseng powder is broken into 40 order meal, adding 20 times of percents by volume of medicinal material weight is that 75% alcohol reflux extracts 2 times, each3h, filters, and merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 12 times of water refluxing extraction of medicinal material weight 2 times again, each 1.5h, mistakeFilter, merging filtrate, obtains pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain that pseudo-ginseng is dry to be soakedCream; Pseudo-ginseng dry extract, adds a small amount of 70% ethanol to dissolve, and by D101 macroporous adsorbent resin column chromatography, first uses 2BV deionized waterWash-out, discards eluent; Be 75% ethanol elution by 4BV percent by volume again, elution speed is 3BV/h, merges ethanol and washesDe-liquid, reclaims solvent, and 80 DEG C dry, obtains arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 resin column, with 2BV deionized water wash-out, discards eluent; With2BV15% ethanolic solution wash-out, discards eluent; Use successively 4BV30%, 4BV50%, 3BV75% ethanol elution, wash-out speedDegree, for 3BV/h, is collected respectively each section of eluent, obtains the eluent of ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, subtractsPress and concentrate, 65 DEG C dry;
(3), by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by weight portion described in claim 1, to obtain final product.
The present invention also provides the pharmaceutical preparation containing above-mentioned composition, and said preparation was by above-mentioned composition and pharmaceutically acceptable yearBody composition.
Described preparation is solid pharmaceutical preparation or liquid preparation, and solid pharmaceutical preparation is tablet, capsule or granule; Liquid preparation isMixture or oral liquid.
Described pharmaceutically acceptable carrier is lactose, starch, dextrin, sweet mellow wine, sucrose, HPMC, friendshipConnection sodium carboxymethylcellulose, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, superfine silica gel powder, pregelatinized starch, sorbierite, hardFatty acid magnesium, talcum powder, HPMC, low-substituted hydroxypropyl cellulose, Sodium Benzoate, potassium sorbate, sucrose or A SiOne or more of Ba Tianzhong, monosodium glutamate, honey, orange flavor.
The preparation method of arasaponin pharmaceutical preparation of the present invention, the method can adopt the preparation of conventional formulation techniqueFor various common formulations.
The present invention also provides above-mentioned composition or preparation to merge the enterogastric diseases such as gastrorrhagia in preparation treatment gastric ulcerThe application of Shi Tigao result for the treatment of.
Inventor finds in research gastric ulcer merges the therapeutic process of hemorrhage of gastrointestinal tract, and panax araliaceae plant has goodGood protection stomach lining, the effect of promotion blood coagulation hemostasis. Notogineng Extract and arasaponin can significantly reduce the stomach of rat and burstUlcer index, the platelet count of increase rat, the prothrombin time of shortening rat, and bad reaction is few. The present invention studies cardThe intestines and stomach microcirculation that has clear improvement of real pseudo-ginseng, Notogineng Extract and arasaponin tool, the effect of protection mucosal lesion, canBe used for the treatment of the enterogastric diseases such as gastric ulcer, hemorrhage of gastrointestinal tract that deficiency-cold in spleen and stomach causes, and there is determined curative effect, safety, useEasy, the feature such as bad reaction is few. Also not exclusively clear to its concrete mechanism of action at present, but arasaponin closes gastric ulcerAnd gastrorrhagia animal model has good the protective effects on gastric mucosa and blood coagulation anastalsis, point out it to there is good treatment stomachUlcer and gastrorrhagia effect.
Therefore, applicant puies forward the group of pseudo-ginseng activity component extract ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1Compound is enough in the new purposes that treatment gastric ulcer merges gastrorrhagia medicine aspect.
The new purposes that composition provided by the invention merges gastrorrhagia medicine aspect for gastric ulcer has the following advantages:
1, the each composition of the present composition extracts and obtains from panax araliaceae plant, and safety non-toxic, can long-term taking.
2, experimental result shows, the gastric ulcer that said composition can significantly reduce gastric ulcer merging gastrorrhagia animal model refers toCount, significantly shorten bleeding time and the clotting time of rat.
Detailed description of the invention
Further illustrate the present invention below by embodiment. It should be understood that embodiments of the invention are for explanationThe present invention instead of limitation of the present invention. The simple modifications that essence according to the present invention is carried out the present invention all belongs to the present inventionClaimed scope. Except as otherwise noted, the percentage of the amount of alcohol in the present invention is percentage by volume, and v/v represents solutionVolume ratio.
Embodiment 1: the preparation of composition of the present invention
(1) take pseudo-ginseng 2kg, be ground into 40 order meal, add 20 times of 75% alcohol reflux of medicinal material weight to extract 2 times, each 3h,Filter, merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 12 times of water refluxing extraction of medicinal material weight 2 times again, and each 1.5h, filters,Merging filtrate, obtains pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain pseudo-ginseng dry extract;Pseudo-ginseng dry extract, adds a small amount of 70% ethanol to dissolve, by D101 macroporous adsorbent resin column chromatography, first with the washing of 2BV deionizationDe-, discard eluent; Use 4BV75% ethanol elution, elution speed is 3BV/h again, merges ethanol eluate, reclaims solvent,80 DEG C dry, obtains arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 macroreticular resin, with 2BV deionized water wash-out, discards eluent; With2BV15% ethanolic solution wash-out, discards eluent; Use successively 4BV30%, 4BV50%, 3BV75% ethanol elution, wash-out speedDegree, for 3BV/h, is collected respectively each section of eluent, obtains the eluent of ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, subtractsPress and concentrate, 65 DEG C dry, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1;
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by following weight portion: 25g, 25g, 15g mix,Obtain.
Embodiment 2: the preparation of composition of the present invention
(1) take pseudo-ginseng 2kg, be ground into 40 order meal, add 15 times of 70% alcohol reflux of medicinal material weight to extract 2 times, each 1h,Filter, merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 10 times of water refluxing extraction of medicinal material weight 2 times again, and each 1h, filters, and closesAnd filtrate, obtain pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain pseudo-ginseng dry extract; ThreeSeven dry extracts, add a small amount of 70% ethanol to dissolve, and by D101 macroporous adsorbent resin column chromatography, first use 1BV deionized water wash-out,Discard eluent; Use 2BV70% ethanol elution, elution speed is 1BV/h again, merges ethanol eluate, reclaims solvent, 80 DEG CDry, obtain arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 macroreticular resin, with 1BV deionized water wash-out, discards eluent; With1BV15% ethanolic solution wash-out, discards eluent; Use successively 2BV30%, 2BV50%, 2BV75% ethanol elution, wash-out speedDegree, for 2BV/h, is collected respectively each section of eluent, obtains the eluent of ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, subtractsPress and concentrate, 65 DEG C dry, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1;
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by following weight portion: 8g, 10g, 5g mix,.
Embodiment 3: the preparation of composition of the present invention
(1) take pseudo-ginseng 2kg, be ground into 40 order meal, add 25 times of 70% alcohol reflux of medicinal material weight to extract 3 times, each 3h,Filter, merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 15 times of water refluxing extraction of medicinal material weight 2 times again, and each 2h, filters, and closesAnd filtrate, obtain pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain pseudo-ginseng dry extract; ThreeSeven dry extracts, add a small amount of 70% ethanol to dissolve, and by D101 macroporous adsorbent resin column chromatography, first use 4BV deionized water wash-out,Discard eluent; Use 3BV70% ethanol elution, elution speed is 1BV/h again, merges ethanol eluate, reclaims solvent, 80 DEG CDry, obtain arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 macroreticular resin, with 4BV deionized water wash-out, discards eluent; With3BV15% ethanolic solution wash-out, discards eluent; Use successively 5BV30%, 5BV50%, 4BV75% ethanol elution, wash-out speedDegree, for 5BV/h, is collected respectively each section of eluent, obtains the eluent of ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, subtractsPress and concentrate, 65 DEG C dry, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1;
(3) by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by following weight portion: 25g, 30g, 20g mix,Obtain.
Embodiment 4: the preparation of composition of the present invention
Get embodiment 1 step (2) gained ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, mix by following weight portion:15g, 15g, 15g mix, and to obtain final product.
Embodiment 5: the preparation of composition of the present invention
Get embodiment 2 steps (2) gained ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, mix by following weight portion:25g, 30g, 20g mix, and to obtain final product.
Embodiment 6: granule of the present invention
Get embodiment 1 resulting composition, add supplementary product starch, sucrose, lactose to mix, with 70% ethanol softwood processed, cross 60 ordersSieve series grain, dry, whole grain, packing, granulation agent, to obtain final product.
Embodiment 7: tablet of the present invention
Get embodiment 2 resulting compositions, add microcrystalline cellulose excipients, hydroxypropyl cellulose, sodium carboxymethyl starch to mix,Add lubricant talcum powder, dolomol to mix, compressing tablet, to obtain final product.
Embodiment 8: capsule of the present invention
Get embodiment 3 resulting compositions, be dried to dried cream powder, after adding the conventional auxiliary material of the capsules such as starch lactose to mix,Production method preparation routinely, pulverizes, sieves, and filling, fit, to obtain final product.
Comparative example 1:
Take pseudo-ginseng 2kg, be ground into 40 order meal, add 20 times of 75% alcohol reflux to extract 2 times, each 3h, filters, and merges filterLiquid, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 12 times of water refluxing extraction 2 times again, and each 1.5h, filters, and merging filtrate, obtains pseudo-ginseng water extractionLiquid; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain pseudo-ginseng dry extract; Pseudo-ginseng dry extract, adds a small amount of70% ethanol dissolves, and by D101 macroporous adsorbent resin column chromatography, first uses 2BV deionized water wash-out, discards eluent; Use again4BV75% ethanol elution, elution speed is 3BV/h, merges ethanol eluate, reclaims solvent, 80 DEG C are dry, obtain pseudo-ginseng totalSaponin(e, adds starch, granulates, and reinstalls capsule, makes capsule.
Pharmacodynamics test:
1 experiment material
1.1 animal used as test
SPF level SD rat, male, 180～220 grams, 10 every group. Buy from Guangxi Medical University's Experimental Animal Center licenseCard SCXK(Hunan) 2015-0003.
1.2 given the test agent and reagent
Embodiment 1, comparative example 1 medicine; Aspirin (Changbaishan Pharmacy Co., Ltd, lot number: 140101); Chloraldurate(Chengdu Ke Long chemical reagent factory, lot number: 2013092101); Formaldehyde (Bo Di chemical inc, Tianjin, lot number:20140401）。
1.3 laboratory apparatus
Anatomical lens with scale, the long ELIASA of EPOCHBIOTEK all-wave (Bai Teng Instrument Ltd. of the U.S.).
2 experimental techniques
2.1 gastric ulcer merge the modeling of gastrorrhagia rat animal model
Get at random 10 as blank group, all the other rat fasting be can't help water after 18 hours, with etherization, were fixed on plankUpper, is immersed in the Water Tank with Temp.-controlled of 23 DEG C, water is in the 30min of xiphoid-process portion, the aspirin that while gavage dosage is 6mg/kg,Dosage is 10ml/kg, every day gavage 2 times, continuously gavage 7 days, preparation gastric ulcer merges gastrorrhagia rat model.
2.2 animal grouping and administrations
After modeling, be divided at random 1 group of model group, positive group and embodiment by body weight. Positive group gives the Aomei that dosage is 4mg/kgDraw azoles, each administration gives corresponding embodiment medicine, and dosage is 20ml/kg, administration every day 1 time, continuous 30 days, blank group andThe isopyknic distilled water of model group gavage.
2.3 collections of specimens and detection
After last administration, fasting be can't help water after 12 hours, from rat tail vein blood sampling, measured platelet counts (/L) and fibrin fermentThe former time (PT). Then use chloral hydrate anesthesia rat, cut abdominal cavity open, ligation pylorus and orifice of the stomach, take out whole stomach, intragastric infusion10% formalin of 5mL, soaks and cuts off along greater curvature after 10 minutes, cleans content, and whole stomach is launched to be laid in glass plateUpper, paper using blots the moisture in ulcer, and a situation arises to observe gastric ulcer, and ulcer level is evaluated, to ulcer levelAssessment method be: by ulcer area and quantity in conjunction with dividing UI, 0: without ulcer; 1:1～3 aphtha (3mm withUnder); 2:3 above aphtha or 1 large ulcer; 3:1 large ulcer and several aphtha; 4: several large ulcer; 5: pierceabilityUlcer; Calculate ulcer inhibition percentage: ulcer inhibition percentage=(model control group UI-administration group UI)/Model control group UI/100%.
3 statistical procedures
Experimental data adopt SPSS carry out statistical procedures, continuous data with± s represents, relatively adopts two sample averages between groupT inspection, between many groups, sample average relatively adopts variance analysis; Think there is significant difference with P < 0.05.
4 experimental results
4.1 impacts on rat gastric ulcer index, experimental result is in table 1
The impact of each group of table 1 on rat ulcer index (±s，n=10)
| Group | Dosage (mg/kg) | UI | Inhibiting rate (%) |
| Blank group | / | 0.90±0.85 | / |
| Model group | / | 4.52±0.76** | / |
| Omeprazole group | 4 | 2.64±0.82△△ | 41.59% |
| 1 group of embodiment | 22.5 | 2.58±0.84△△## | 42.92% |
| 4 groups of embodiment | 22.5 | 2.61±1.02△△## | 41.25% |
| 1 group of comparative example | 48 | 3.20±0.75△ | 35.86% |
Note: with the comparison of blank group, * * p < 0.01, * p < 0.05; With model group comparison, △ △ P < 0.01, △ P <0.05；##p＜0.01，#p＜0.05。
4.2 impacts on rat platelet counting (/L) and prothrombin time (PT), experimental result is in table 2
The impact of table 2 on rat platelet counting and prothrombin time
| Group | Dosage (mg/kg) | Platelet count (109/L） | PT（s） |
| Blank group | 470.29±45.84 | 10.56±3.58 | |
| Model group | 379.56±30.72** | 18.27±3.71** | |
| Omeprazole group | 4 | 453.88±42.63△△ | 12.86±4.32△△ |
| 1 group of embodiment | 22.5 | 449.05±38.67△△## | 13.45±5.26△ |
| 4 groups of embodiment | 22.5 | 451.37±36.28△△## | 12.92±5.31△△ |
| 1 group of comparative example | 48 | 419.75±30.58△ | 15.83±4.65 |
Note: with the comparison of blank group, * * p < 0.01, * p < 0.05; With model group comparison, △ △ P < 0.01, △ P <0.05；##p＜0.01，#p＜0.05。
Conclusion: experimental result demonstration, model group rat platelet counting is obviously less than blank group, and ulcer indexWith the clotting time more than Normal group. Each administration group platelet count is apparently higher than model group, when ulcer index and blood coagulationBetween all lower than model group, with comparative example comparison, each embodiment group platelet count is apparently higher than comparative example group, ulcer index andClotting time, between above group, index comparing difference all had significant difference (P < 0.05 or P < 0.01) all lower than comparative example group. SayThe bright present composition has good protection stomach lining, promotes the effect of blood coagulation hemostasis, can effectively treat gastric ulcer and mergeThe enterogastric diseases such as gastrorrhagia, and result for the treatment of is obviously better than prior art.
Although, above use general explanation, detailed description of the invention and test, the present invention has been done to detailed retouchingState, but on basis of the present invention, can make some modifications or improvements it, this is apparent to those skilled in the art. Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the present invention claimedScope.
Claims (8)
1. a composition for the treatment of gastric ulcer merging hemorrhage of gastrointestinal tract, is characterized in that, described composition is by following weight portionOne-tenth be grouped into:
Ginsenoside Re: 8～25 parts, ginseng sapoglycoside Rg 3: 10～30 parts, ginsenoside Rh 1: 5～20 parts.
2. treatment gastric ulcer according to claim 1 merges the composition of hemorrhage of gastrointestinal tract, it is characterized in that described combinationThing is grouped into by the one-tenth of following weight portion:
Ginsenoside Re: 15～25 parts, ginseng sapoglycoside Rg 3: 15～30 parts, ginsenoside Rh 1: 15～20 parts.
3. treatment gastric ulcer according to claim 2 merges the composition of hemorrhage of gastrointestinal tract, it is characterized in that described combinationThing is made up of the following composition of weight portion proportioning: ginsenoside Re: 25 parts, ginseng sapoglycoside Rg 3: 25 parts, ginsenoside Rh 1: 15Part.
4. treatment gastric ulcer according to claim 2 merges the composition of hemorrhage of gastrointestinal tract, it is characterized in that preparation methodComprise the steps:
(1) Radix Notoginseng powder is broken into meal, adding percent by volume is that 70-80% alcohol reflux extracts 2～3 times, each 1～3h, mistakeFilter, merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 10-15 times of water refluxing extraction of medicinal material weight 2 times again, each 1～2h, mistakeFilter, merging filtrate, obtains pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, concentrated, dry, obtain pseudo-ginseng dry extract; Pseudo-ginseng is dryMedicinal extract, adds a small amount of ethanol to dissolve, and by D101 macroporous adsorbent resin column chromatography, first uses 1-4BV deionized water wash-out, discards and washesDe-liquid; Be 70-80% ethanol elution by 2-6BV percent by volume again, elution speed is 1～3BV/h, merges ethanol elutionLiquid, reclaims solvent, dry, obtains arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 resin column, with 1～4BV deionized water wash-out, discards eluent;With 1～3BV15% ethanolic solution wash-out, discard eluent; Use successively 2～5BV30%, 2～5BV50%, 2～4BV75%Ethanol elution, elution speed is 2～5BV/h, collects respectively each section of eluent, obtains ginsenoside Re, ginseng sapoglycoside Rg 3, ginsengThe eluent of saponin(e Rh1, reduced pressure concentration, dry;
(3), by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by weight portion described in claim 1, to obtain final product.
5. treatment gastric ulcer according to claim 4 merges the composition of hemorrhage of gastrointestinal tract, it is characterized in that preparation methodComprise the steps:
(1) Radix Notoginseng powder is broken into 40 order meal, adding 20 times of percents by volume of medicinal material weight is that 75% alcohol reflux extracts 2 times, each3h, filters, and merging filtrate, obtains pseudo-ginseng alcohol extract; The dregs of a decoction add 12 times of water refluxing extraction of medicinal material weight 2 times again, each 1.5h, mistakeFilter, merging filtrate, obtains pseudo-ginseng water extract; Merge pseudo-ginseng alcohol extract and water extraction liquid, 80 DEG C of reduced pressure concentrations, dry, obtain that pseudo-ginseng is dry to be soakedCream; Pseudo-ginseng dry extract, adds a small amount of 70% ethanol to dissolve, and by D101 macroporous adsorbent resin column chromatography, first uses 2BV deionized waterWash-out, discards eluent; Be 75% ethanol elution by 4BV percent by volume again, elution speed is 3BV/h, merges ethanol and washesDe-liquid, reclaims solvent, and 80 DEG C dry, obtains arasaponin;
(2), after arasaponin is dissolved in water, upper HPD-100 resin column, with 2BV deionized water wash-out, discards eluent; With2BV15% ethanolic solution wash-out, discards eluent; Use successively 4BV30%, 4BV50%, 3BV75% ethanol elution, wash-out speedDegree, for 3BV/h, is collected respectively each section of eluent, obtains the eluent of ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1, subtractsPress and concentrate, 65 DEG C dry;
(3), by ginsenoside Re, ginseng sapoglycoside Rg 3, ginsenoside Rh 1 mix by weight portion described in claim 1, to obtain final product.
6. treat a preparation for gastric ulcer merging hemorrhage of gastrointestinal tract, by the treatment gastric ulcer described in claims 1 to 3 any oneThe composition that merges hemorrhage of gastrointestinal tract can prepare and form with the carrier of pharmaceutically accepting.
7. treatment gastric ulcer according to claim 6 merges the preparation of hemorrhage of gastrointestinal tract, it is characterized in that described medicine and pharmacologyThe carrier of upper acceptance comprises: lactose, starch, dextrin, sweet mellow wine, sucrose, HPMC, cross-linked carboxymethyl celluloseSodium, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, superfine silica gel powder, pregelatinized starch, sorbierite, dolomol, talcum powder,In HPMC, low-substituted hydroxypropyl cellulose, Sodium Benzoate, potassium sorbate, sucrose or Aspartame, monosodium glutamate, honeybeeThe mixing of any one or more in honey, orange flavor.
8. treatment gastric ulcer according to claim 6 merges the preparation of hemorrhage of gastrointestinal tract, it is characterized in that described medicine systemAgent comprises capsule, tablet, granule, mixture, oral liquid, syrup etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610097583.3A CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610097583.3A CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105582017A true CN105582017A (en) | 2016-05-18 |
| CN105582017B CN105582017B (en) | 2019-03-29 |
Family
ID=55922176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610097583.3A Active CN105582017B (en) | 2016-02-23 | 2016-02-23 | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105582017B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974952A (en) * | 2017-04-10 | 2017-07-25 | 通化鑫业生物科技研发有限公司 | Application of the fresh ginseng activity extract in treatment oral cavity and digestive tract ulcer medicine is prepared |
| WO2019056592A1 (en) * | 2017-09-25 | 2019-03-28 | 中国医学科学院药用植物研究所 | Novel use of combination or composition of panax notoginseng and aspirin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857352A (en) * | 2006-03-29 | 2006-11-08 | 广西梧州制药（集团）股份有限公司 | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases |
| CN101732378A (en) * | 2010-01-15 | 2010-06-16 | 黑龙江省珍宝岛制药有限公司 | Radix notoginseng extract and preparation thereof |
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
-
2016
- 2016-02-23 CN CN201610097583.3A patent/CN105582017B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857352A (en) * | 2006-03-29 | 2006-11-08 | 广西梧州制药（集团）股份有限公司 | Notoginseng medicine composition for treating cardiac and cerebral vascular diseases |
| CN101732378A (en) * | 2010-01-15 | 2010-06-16 | 黑龙江省珍宝岛制药有限公司 | Radix notoginseng extract and preparation thereof |
| CN101897990A (en) * | 2010-07-06 | 2010-12-01 | 大连理工大学 | Dressing composition used for inhibiting scars and accelerating wound healing and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨琳 等: "三七总皂苷药理作用的研究进展", 《安徽医药》 * |
| 闫红敏: "自拟溃疡散治疗慢性胃炎150例", 《中国医药指南》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974952A (en) * | 2017-04-10 | 2017-07-25 | 通化鑫业生物科技研发有限公司 | Application of the fresh ginseng activity extract in treatment oral cavity and digestive tract ulcer medicine is prepared |
| WO2019056592A1 (en) * | 2017-09-25 | 2019-03-28 | 中国医学科学院药用植物研究所 | Novel use of combination or composition of panax notoginseng and aspirin |
| JP2020537687A (en) * | 2017-09-25 | 2020-12-24 | 中国医学科学院薬用植物研究所 | New use of combination or combination of 37 and aspirin |
| US11883452B2 (en) | 2017-09-25 | 2024-01-30 | Chinese Academy Of Medical Sciences Institute Of Medicinal Plant Development | Use of combination or composition of Radix et Rhizoma Notoginseng and aspirin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105582017B (en) | 2019-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| KR20150096798A (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
| CN108403882B (en) | Salvia miltiorrhiza composition for treating coronary heart disease and preparation method thereof | |
| CN113262268A (en) | Traditional Chinese medicine composition for clearing lung and eliminating phlegm and application thereof in treating lung diseases | |
| CN105582017B (en) | A kind of composition and preparation method thereof treated gastric ulcer and merge hemorrhage of gastrointestinal tract | |
| CN115919977A (en) | Chinese medicinal formula for treating new coronavirus infection pathopoiesia and preparation method thereof | |
| CN105497133A (en) | Periplaneta Americana medicine composition for treating pharyngitis and tonsillitis and preparation method thereof | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN109481515B (en) | Solid dispersion effervescent tablet with digestion promoting function | |
| CN102232982A (en) | Extract product of herba cephalanoploris effective position, preparation method thereof and purpose thereof | |
| CN104173598A (en) | Composition for treating gastritis and peptic ulcer and preparation method thereof | |
| CN102885915B (en) | Preparation method of controlled-release capsule with functions of detoxifying and diarrhea stopping | |
| CN103356798A (en) | Application of chronic-gastritis-treating traditional Chinese medicine in preparing medicine used for preventing gastric ulcer | |
| CN117323402B (en) | Pharmaceutical composition for treating enteritis and preparation method thereof | |
| CN115531493B (en) | Compound preparation and preparation method thereof | |
| CN101366831B (en) | Rhubarb polyoses, preparation method, medicament composition and uses | |
| CN101926848B (en) | Medicinal composition for treating heart cerebrovascular diseases and preparation thereof | |
| CN102247417B (en) | Fat reduction effect of total saponins and polysaccharides of Panax japonicus | |
| CN105687878A (en) | Traditional Chinese medicine for treating subacute thyroiditis and preparation method thereof | |
| CN105687443A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN105853917B (en) | A kind of pharmaceutical composition and its preparation method and application for treating chronic pharyngitis | |
| CN105168844A (en) | Medicine for treating portal hypertension postoperative treating thrombosis | |
| CN106620440B (en) | Prescription for cough | |
| CN115444900A (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method and application thereof | |
| CN103735591A (en) | Composition for treating digestive ulcer and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |